Bml-210, HDAC inhibitor

Get basic and detailed information about product. Buying link available


Catalog numberSIH-348-5MG
NameBml-210, HDAC inhibitor
Size5 mg
Go to shop


Stock availabilitIn StockIn Stock
CAS number537034-17-6
DescriptionHDAC inhibitor
Molecular weight339,4 g/mol
Primary research fieldsCell Signaling, Epigenetics, Cancer
Other nameN1-(2-aminophenyl)-N8-phenyloctanediamide
Product categorySmall Molecules
Product typeInhibitor
Chemical formulaC20H25N3O2
Purity pourcentage>98% (TLC), NMR conforms
Soluble inSoluble in 25 mg/ml DMSO or 10 mg/ml Ethanol
Physical appearanceTan Solid
Storage recommendations-20ºC
Shipping recommendationsShipped Ambient
Safety informationClassification: Caution- Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection S24/25- Avoid contact with skin and eyes Hazard Statements: H413 – May cause long lasting harmful effects to aquatic life.
PubChem number9543540
Scientific contextA novel non-hydroxamic acid HDAC inhibitor. IC50=5-10 µM (HeLa nuclear extract). Induces growth inhibition, proapoptotic and differentiation effects on human leukemia cell lines.
Bibliography1. Savickiene J., et al. (2006) Eur. J. Pharmacol. 549: 9. 2. Herman D., et al. (2006) Nature Chem. Biol. 10: 551.
Release date1-Aug-2012
PubMed numberRefer to PubMed
Tested applicationsTo be tested
Tested reactivityTo be tested
Representative figure legendChemical structure of BML-210 (SIH-348), a HDAC inhibitor. CAS #: 537034-17-6. Molecular Formula: C20H25N3O2 . Molecular Weight: 339.4 g/mol. Chemical structure of BML-210, a HDAC inhibitor (SIH-348). CAS # 537034-17-6. Molecular Formula: C20H25N3O2 .
Warning informationNon-hazardous
Country of productionCanada
Total weight (kg)0.25
Net weight (g)0.005
Additional descriptionTissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.